跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT01396525
NCT01396525已完成3 期

A Prospective, Non-randomized, Two Arm, Multi-center Clinical Trial to Evaluate the Safety and Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System and the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.

Abbott Medical Devices1 个研究点 分布在 1 个国家目标入组 153 人开始时间: 2009年3月1日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
153
试验地点
1
主要终点
Major Adverse Event (MAE)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

To determine the safety and efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in subjects with atherosclerotic de novo or restenotic lesions in the native common iliac artery and/or native external iliac artery.

详细描述

The MOBILITY study was a prospective, non-randomized, two-arm, multi-center study. The 2 arms (Omnilink Elite arm and Absolute Pro arm) were designed to independently assess the safety and effectiveness of the 2 devices used in this study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 89 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Clinical Inclusion Criteria:
  • •Subject must be at least 18 and < 90 years of age.
  • •Subject has been informed of the nature of the trial, agrees to its provisions, and has signed the informed consent form.
  • •Subject must agree to undergo all protocol-required follow-up examinations and requirements at the investigational site.
  • •History of symptomatic claudication (Rutherford Becker Clinical Category 2-3) or ischemic rest pain (Rutherford Becker Clinical Category 4).
  • •Female subjects of childbearing potential must have had a negative pregnancy test before treatment, and must not be nursing at the time of treatment, and agree at time of consent to use birth control during participation in this trial up to and including the follow-up at 9 months.
  • •Angiographic Inclusion Criteria
  • •Up to two bilateral de novo or restenotic lesions of the native common iliac artery and/or native external iliac artery may be treated(one per side).
  • •Common iliac artery lesion visually estimated to be ≥50% stenosis and ≤100% stenosis (total occlusion)
  • •External iliac artery lesion visually estimated to be ≥50% stenosis and ≤99% stenosis
  • •Lesion length for stenosis of the common or external iliac artery visually estimated to be ≥ 10 mm and ≤ 110 mm (Absolute Pro)
  • •Lesion length for total occlusion of the common iliac artery visually estimated to be ≤40 mm
  • •Target vessel reference diameter visually estimated to be ≥3.6 mm and ≤9.1 mm (Absolute Pro)
  • •On the treatment side(s), patent superficial femoral and popliteal arteries and at least one patent distal outflow artery with in-line distal vessel flow to the foot as confirmed by arteriography. Patent is defined as < 50% stenosis.
  • •Lesion length for stenosis of the common or external iliac artery visually estimated to be ≥ 10 mm and ≤ 50 mm (Omnilink Elite).
  • •Target vessel reference diameter visually estimated to be ≥ 5.0 mm and ≤ 11.0 mm (Omnilink Elite).

排除标准

  • •Subject is unable to walk.
  • •Subject has had recent major surgery (last 3 months) e.g., abdominal surgery, coronary artery bypass graft surgery, thoracic surgery.
  • •Subject has received, or is on the waiting list for a major organ transplant (heart, lung, kidney, liver).
  • •Subject is diagnosed as Rutherford Becker Clinical Category 0, 1, 5, or
  • •Subject has ulcers or lesions on the lower extremity(ies) of the target lesion side(s).
  • •Subject has elevated serum creatinine > 2.0 mg/dl.
  • •Subject has uncontrolled diabetes mellitus (DM) (serum glucose > 400 mg/dl).
  • •Subject has had a myocardial infarction(MI)(Q-wave or NQWMI) within the previous 30 days.
  • •Subject has had a stroke within the previous 30 days and/or has deficits from a prior stroke that limits the subjects ability to walk.
  • •Subject has unstable angina defined as rest angina with ECG changes.
  • •Subject has a groin infection, or an acute systemic infection that is currently under treatment.
  • •Subject has acute thrombophlebitis or deep vein thrombosis in either extremity.
  • •Subject requires any planned procedure within 30 days after the index procedure that would necessitate the discontinuation of aspirin, clopidogrel or ticlopidine following the procedure.
  • •Subject has other medical illnesses (e.g., cancer or congestive heart failure) that may cause the subject to be non-compliant with protocol requirements, confound the data interpretation, or is associated with limited life-expectancy (i.e., less than 2 years).
  • •Subject is currently participating in an investigational drug or device trial that has not completed the primary endpoint follow-up or that clinically interferes with the current trial endpoints.
  • •Subject is unable to understand or unwilling to cooperate with trial procedures or is unwilling or unable to return to the treatment center for follow-up visits.
  • •If intended stent is Absolute Pro, subject has known hypersensitivity or contraindication to nickel, titanium or platinum; subject has known hypersensitivity or contraindication to standard intraprocedure anticoagulant(s); subject has sensitivity to contrast which cannot be adequately pre-treated with medication.
  • •Subject has known allergy or contraindication to aspirin or clopidogrel (Plavix®); if allergy or contraindication is to clopidogrel, subject is unable to tolerate ticlopidine (Ticlid®).
  • •Subject has known bleeding disorder or hypercoagulable disorder, or will refuse blood transfusions.
  • •Subject has suffered a gastrointestinal (GI) bleed within 30 days before the index procedure that would interfere with antiplatelet therapy.
  • •If intended stent is Omnilink Elite, subject has known hypersensitivity or contraindication to cobalt chromium; subject has known hypersensitivity or contraindication to standard intraprocedure anticoagulant(s); subject has sensitivity to contrast which cannot be adequately pre-treated with medication.
  • •Requirement of general anesthesia or spinal block for the procedure.
  • •Presence of contralateral limb amputation that was performed to treat any non-traumatic disease in that limb, e.g. atherosclerotic, vascular, neuropathic.
  • •Presence of bypass conduit in any outflow vessel, i.e. SFA, popliteal, anterior tibial, posterior tibial, peroneal, ipsilateral to the target lesion.
  • •Subject requires a concomitant percutaneous endovascular procedure in another vessel, e.g. coronary.
  • •Target lesion is in an iliac artery that has been previously stented.
  • •Angiographic Exclusion Criteria
  • •Subject has a totally occluded (100% stenosis) external iliac artery ipsilateral to the target lesion.
  • •Subject has a totally occluded (100% stenosis) outflow artery (SFA) ipsilateral to the target lesion
  • •Target lesion is within or adjacent to an aneurysm.
  • •Lesion is located within or beyond a vessel that contains a bypass graft.
  • •Lesion(s) requires atherectomy (or ablative devices) to facilitate stent delivery.
  • •Subject has a history of aortic revascularization or has an abdominal aortic aneurysm > 3cm.
  • •Lesion extends beyond the inguinal ligament.
  • •Subject has angiographic evidence of thrombus in the target disease segment or vessel that is unresponsive to anti-thrombotic therapies.
  • •Subject has multilevel disease in the target extremity that requires other staged procedures within 30 days before or after the procedure.
  • •On the treatment side(s), subject is without patent superficial femoral and popliteal arteries and at least one patent distal outflow artery with in-line distal vessel flow to the foot as confirmed by arteriography. Patent is defined as < 50% stenosis.
  • •Requirement for > 1 stent to treat full length of lesion.

研究组 & 干预措施

Omnilink Elite™ Peripheral Balloon-Expandable Stent System

Experimental

干预措施: Omnilink Elite™ Peripheral Balloon-Expandable Stent System (Device)

结局指标

主要结局

Major Adverse Event (MAE)

时间窗: 9 months

Defined as death, myocardial infarction (MI), clinically-driven target lesion revascularization, and limb loss (major amputation only) on the treated side(s).

次要结局

  • Restenosis(3 years)
  • Technical Success(Acute: from beginning of index procedure to end of procedure)
  • Thigh Brachial Index (TBI) for the Treated Limb(s)(3 years)
  • Walking Impairment Questionaire Scores(3 years)
  • Procedure Success(Beginning of index procedure to 2 days post-index procedure or discharge, whichever is sooner)
  • Kaplan-Meier Estimate of Freedom From Target Vessel Revascularization (TVR) for the Treated Limb(s)(3 years)
  • Kaplan-Meier Estimate of Freedom From Clinically-driven Target Vessel Revascularization (CD-TVR) for the Treated Limb(s)(1 month and 9 months)
  • Kaplan-Meier Estimate of Freedom From Clinically DrivenTarget Vessel Revascularization (TVR) for the Treated Limb(s)(3 years)
  • Kaplan-Meier Estimate of Freedom From Embolic Events(3 years)
  • Stent Thrombosis(1 month)
  • Changes in Quality of Life Measures: Physical Component Summary(Baseline and 3 years)
  • Changes in Quality of Life Measures: Mental Component Summary(Baseline and 3 years)
  • Changes in Thigh Brachial Index (TBI) for the Treated Limb(s)(Between baseline and 3 years)
  • Kaplan-Meier Estimate of Freedom From Target Lesion Revascularization (TLR)(3 years)
  • Kaplan-Meier Estimate of Freedom From Clinically-driven Target Lesion Revascularization (CD-TLR)(3 years)
  • Kaplan-Meier Estimate of Freedom From Clinically-driven Target Vessel Revascularization (TVR) for the Treated Limb(s)(18 months)
  • Kaplan-Meier Estimate of Freedom From Clinically Driven Target Vessel Revascularization (TVR) for the Treated Limb(s)(2 years)
  • Kaplan-Meier Estimate of Freedom From Target Extremity Revascularization (TER) for the Treated Limb(s)(3 years)
  • Kaplan-Meier Estimate of Freedom From Death (All Cause)(3 years)
  • Rutherford Becker Clinical Category for the Treated Limb(s)(3 years)
  • Changes From Baseline in Rutherford Becker Clinical Category for the Treated Limb(s)(Baseline and 3 years)
  • Primary Stent Patency(3 years)
  • Kaplan-Meier Estimate of Freedom From Amputations (Major) of the Treated Limb(s)(3 years)
  • Kaplan-Meier Estimate of Freedom From Myocardial Infarction (MI)(3 years)
  • Kaplan-Meier Estimate of Freedom From Amputations (Minor) of the Treated Limb(s)(3 years)
  • Device Success(Acute: from beginning of index procedure to end of procedure)
  • Thigh Brachial Index (TBI) for the Treated Limb(s)(Pre-procedure)
  • Thigh Brachial Index (TBI) for the Treated Limb(s)(Post-Procedure)
  • Thigh Brachial Index (TBI) for the Treated Limb(s)(1 month)
  • Thigh Brachial Index (TBI) for the Treated Limb(s)(9 months)
  • Thigh Brachial Index (TBI) for the Treated Limb(s)(2 years)
  • Changes in Thigh Brachial Index (TBI) for the Treated Limb(s)(Between baseline and Post-procedure)
  • Changes in Thigh Brachial Index (TBI) for the Treated Limb(s)(Between Baseline and 1 month)
  • Changes in Thigh Brachial Index (TBI) for the Treated Limb(s)(Between baseline and 9 months)
  • Changes in Thigh Brachial Index (TBI) for the Treated Limb(s)(Between baseline and 2 years)
  • Walking Impairment Questionaire Scores(Pre-procedure)
  • Walking Impairment Questionaire Scores(1 month)
  • Walking Impairment Questionaire Scores(9 months)
  • Walking Impairment Questionaire Scores(2 years)
  • Rutherford Becker Clinical Category for the Treated Limb(s)(Pre-Procedure)
  • Rutherford Becker Clinical Category for the Treated Limb(s)(1 month)
  • Rutherford Becker Clinical Category for the Treated Limb(s)(9 months)
  • Rutherford Becker Clinical Category for the Treated Limb(s)(2 years)
  • Changes From Baseline in Rutherford Becker Clinical Category for the Treated Limb(s)(Between baseline and 1 month)
  • Changes From Baseline in Rutherford Becker Clinical Category for the Treated Limb(s)(Between baseline and 9 months)
  • Changes From Baseline in Rutherford Becker Clinical Category for the Treated Limb(s)(Baseline and 2 years)
  • Kaplan-Meier Estimate of Freedom From Target Lesion Revascularization (TLR)(1 month and 9 months)
  • Kaplan-Meier Estimate of Freedom From Target Lesion Revascularization (TLR)(18 months)
  • Kaplan-Meier Estimate of Freedom From Target Lesion Revascularization (TLR)(2 years)
  • Kaplan-Meier Estimate of Freedom From Clinically-driven Target Lesion Revascularization (CD-TLR)(1 month and 9 months)
  • Kaplan-Meier Estimate of Freedom From Clinically-driven Target Lesion Revascularization (CD-TLR)(18 months)
  • Kaplan-Meier Estimate of Freedom From Clinically-driven Target Lesion Revascularization (CD-TLR)(2 years)
  • Kaplan-Meier Estimate of Freedom From Target Vessel Revascularization (TVR) for the Treated Limb(s)(1 month and 9 months)
  • Kaplan-Meier Estimate of Freedom From Target Vessel Revascularization (TVR) for the Treated Limb(s)(18 months)
  • Kaplan-Meier Estimate of Freedom From Target Vessel Revascularization (TVR) for the Treated Limb(s)(2 years)
  • Kaplan-Meier Estimate of Freedom From Target Extremity Revascularization (TER) for the Treated Limb(s)(1 month and 9 months)
  • Kaplan-Meier Estimate of Freedom From Target Extremity Revascularization (TER) for the Treated Limb(s)(18 months)
  • Kaplan-Meier Estimate of Freedom From Target Extremity Revascularization (TER) for the Treated Limb(s)(2 years)
  • Primary Stent Patency(1 month)
  • Kaplan-Meier Estimate of Freedom From Death (All Cause)(2 years)
  • Primary Stent Patency(9 months)
  • Primary Stent Patency(2 years)
  • Restenosis(9 months)
  • Restenosis(2 years)
  • Kaplan-Meier Estimate of Freedom From Death (All Cause)(1 month and 9 months)
  • Kaplan-Meier Estimate of Freedom From Death (All Cause)(18 months)
  • Kaplan-Meier Estimate of Freedom From Myocardial Infarction (MI)(1 month and 9 months)
  • Kaplan-Meier Estimate of Freedom From Myocardial Infarction (MI)(18 months)
  • Kaplan-Meier Estimate of Freedom From Myocardial Infarction (MI)(2 years)
  • Kaplan-Meier Estimate of Freedom From Amputations (Major) of the Treated Limb(s)(1 month and 9 months)
  • Kaplan-Meier Estimate of Freedom From Amputations (Major) of the Treated Limb(s)(18 months)
  • Kaplan-Meier Estimate of Freedom From Amputations (Major) of the Treated Limb(s)(2 years)
  • Kaplan-Meier Estimate of Freedom From Embolic Events(1 month and 9 months)
  • Kaplan-Meier Estimate of Freedom From Embolic Events(18 months)
  • Kaplan-Meier Estimate of Freedom From Embolic Events(2 years)
  • Kaplan-Meier Estimate of Freedom From Amputations (Minor) of the Treated Limb(s)(1 month and 9 months)
  • Kaplan-Meier Estimate of Freedom From Amputations (Minor) of the Treated Limb(s)(18 months)
  • Kaplan-Meier Estimate of Freedom From Amputations (Minor) of the Treated Limb(s)(2 years)
  • Changes in Quality of Life Measures: Physical Component Summary(Baseline and 1 month)
  • Changes in Quality of Life Measures: Physical Component Summary(Baseline and 9 months)
  • Changes in Quality of Life Measures: Physical Component Summary(Baseline and 2 years)
  • Changes in Quality of Life Measures: Mental Component Summary(Baseline and 1 month)
  • Changes in Quality of Life Measures: Mental Component Summary(Baseline and 9 months)
  • Changes in Quality of Life Measures: Mental Component Summary(Baseline and 2 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
3 期
Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.Peripheral Vascular Disease
NCT00844532Abbott Medical Devices151
已完成
3 期
Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac ArteriesIntermittent ClaudicationAtherosclerotic DiseaseArterial Occlusive DiseaseThrombosis
NCT00352222Boston Scientific Corporation150
已完成
不适用
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive DiseasePeripheral Artery DiseasePeripheral Vascular DiseaseArterial Occlusive Disease
NCT02228564C. R. Bard155
已完成
不适用
EPIC US Pivotal StudyPercutaneous Intervention of the Carotid Arteries.
NCT00460187Lumen Biomedical237
已完成
不适用
A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery DiseasePeripheral Arterial Disease
NCT03941314Kantonsspital Winterthur KSW300